Author:
Janssen Julie M.,Van Calsteren Kristel,Dorlo Thomas P. C.,Halaska Michael J.,Fruscio Robert,Ottevanger Petronella,Schröder Carolien P.,Boere Ingrid,Witteveen Petronella O.,Painter Rebecca C.,Bekkers Ruud,Drochytek Vit,Beijnen Jos H.,Huitema Alwin D. R.,Amant Frederic C. H.
Funder
European Research Council
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference30 articles.
1. FDA Guidance for Industry – Pharmaockinetics in Pregnancy – Study Design, Data Analysis, and Impact on Dosing and Labeling. FDA Guidance. US FDA; 2004.
2. FDA Guidance for Industry – Establishing Pregnancy Exposure Registries. FDA Guidance. US FDA; 2002.
3. European Medicines Agency (EMA). Guideline on the exposure to medicinal products during pregnancy: need for post-authorization data. London: European Medicines Agency; 2006.
4. de Haan J, Verheecke M, Van Calsteren K, Van CB, Shmakov RG, Gziri MM, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19:337–46.
5. Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824–34.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献